Duncan McHale, MBBS MRCP PhD, joined SV as a Venture Partner in 2020. He is chief medical officer of Evelo Biosciences and a director at Zarodex Therapeutics, both SV portfolio companies.
Duncan is a clinical geneticist and early drug development expert. He joined Evelo Biosciences after co-founding Weatherden, a consultancy and execution firm that specialises in de-risking drug discovery and drug development with Houman Ashrafian. Prior to that, he spent six years at UCB Pharma, where he was vice president and head of Global Early Development. In that time, he took eight programs including large molecule, small molecules, inflammation, neuroscience and rare diseases into development with four reaching proof of concept. One program has now completed Phase III and is approaching submission.
Prior to UCB, Duncan spent 17 years focusing on pharmacogenetics, early development and personalised medicine as vice president for Personalised Healthcare and Biomarkers at AstraZeneca, and European head of Translational Molecular Medicine at Pfizer. In his career, he has worked across many therapeutic areas, including inflammation, oncology, neuroscience, cardiovascular, metabolic and respiratory disease and registered multiple patents.
Duncan trained in General Adult Medicine at Newcastle University and obtained a PhD in genetics from the University of Leeds. He has sat on multiple Medical Research Council panels and authored the ICH E15 and E16 guidelines focusing on biomarker development and qualification, as well as of more than 40 peer-reviewed scientific publications across multiple therapeutic areas. Duncan was also the IMI’s lead on call for Molecular Taxonomy of Human Disease, chaired the EFPIA Pharmacogenomics Working Group, and advised the Department of Health on its Emerging Science and Bioethics Advisory Committee.